Immune boosting with PRaG-1 treatment
Part of Cancer clinical trials.
This trial tests a new combination treatment called PRaG-1 that may help your immune system fight cancer. It combines radiation therapy with a drug to boost immune response, and may be an option if standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must not have had another cancer (except certain skin or early cervical cancers) in the past 5 years.
- You must not have a serious heart condition, such as heart failure, irregular heartbeat needing medicine, or a heart attack in the last year.
- You must not be currently taking drugs that weaken your immune system.
- You must not have a serious active infection or a condition like HIV or a history of organ transplantation.
- You must not have known allergies to any of the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a supplement derived from cordyceps mushrooms to see if it can raise low CD8+ immune cell levels in people who have had solid tumors. It may help strengthen your immune system after previous cancer treatments.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This trial tests an experimental drug called RP-001 in people with advanced or metastatic cancer that has not improved with standard treatment. It aims to see if the drug is safe and how well it works.
This trial tests an experimental drug, IMC-P115C, for people with advanced cancers that have a specific marker called PRAME and a genetic type HLA-A*02:01. It may be an option if other treatments have stopped working or caused side effects.
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.